Denali Therapeutics Inc. (DNLI)
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Address
161 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO, CA 94080
Founded
2013
Number of Employees
445
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)
Never miss an email alert when insiders at DNLI make a trade.
Creating a free account takes less than one minute